Clinical Trial Update: Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy and safety of 1% pimecrolimus cream in children aged 2 to 11 with mild-to-moderate facial atopic dermatitis; the study has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Pimecrolimus Cream 1% (pimecrolimus)

Snippet

Sponsor: Novartis | Conditions: Atopic Dermatitis | Phase 4 | Status: COMPLETED